Pierre Fabre introduced on Thursday, Could 28, an almost EUR 50 million (USD 58 million) funding to double manufacturing capability at its Avène plant in southern France by 2029. The undertaking will modernize and develop the power, which is fully devoted to manufacturing and packaging merchandise beneath the Eau Thermale Avène model, as the corporate seeks to fulfill robust worldwide demand, notably in China and the US.
The Pierre Fabre Group goals to double the location’s annual manufacturing capability from 100 million to 200 million items by 2029.
The corporate mentioned the growth and modernization of the plant, devoted to its flagship skincare model, varieties a part of a broader EUR 250 million industrial funding program spanning 2023 to 2027.
The Avène unit, which employs 330 individuals, homes manufacturing, packaging, and a warehouse, supplemented by two exterior logistics websites.
In 2025, Pierre Fabre generated EUR 3.2 billion in income, with worldwide markets accounting for 71% of gross sales. The group, which employs 10,000 individuals worldwide, manufactures practically 90% of its merchandise in France.
The group’s dermo-cosmetics gross sales rose by 2.6% in contrast with 2024, pushed specifically by robust efficiency from the Eau Thermale Avène model, which grew 3.9% at fixed change charges over the 12 months.
Pierre Fabre’s dermo-cosmetics portfolio additionally contains Ducray, Dexeryl, Klorane, A-Derma, René Furterer, Même Cosmetics, and Elgydium.
